Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06080789 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis

A Phase 2 study of Acute Pancreatitis, sponsored by Panafina.

Recruiting
Registry status
Phase 2
Development phase
36
Enrollment target
14
Study locations

NCT06080789 is a Phase 2 study of Acute Pancreatitis that is actively recruiting participants, run by Panafina. The registered enrollment target is 36 participants, below the 2,315-participant average among 10 other Acute Pancreatitis trials with a reported enrollment target (98% lower). The trial reports 14 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06080789, a Phase 2 study of Acute Pancreatitis, is actively recruiting participants, sponsored by Panafina.

RECRUITING
Registry status
Phase 2
Development phase
36 participants
Enrollment target
14
Study locations

Study Summary

The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis. The main question the study aims to answer is: • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection safe in patients with predicted severe acute pancreatitis. The study also aims to answer: • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection effective in treating patients with predicted severe acute pancreatitis. Study participants will be randomly assigned (like the flip of a coin) to receive a single dose of RABI-767 plus supportive care or supportive care only. The study sponsor will compare safety and efficacy data collected from participants who receive RABI-767 to participants who receive supportive care only to test if RABI-767 is safe and effective.

Conditions Studied

Acute Pancreatitis

Interventions

  • DRUG RABI-767

Study Locations (14)

Florida

  • University of Florida Health - Gainesville
  • Orlando Health - Orlando

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

California

  • Keck Hospital of USC and LA County Hospital - Los Angeles

Colorado

  • University of Colorado Anschutz Medical Campus - Aurora

Illinois

  • UI Health, University of Illinois Chicago Hospital Health Sciences System - Chicago

Indiana

  • Indiana University Health University Hospital - Indianapolis

Maryland

  • Johns Hopkins Hospital - Baltimore

Michigan

  • Henry Ford Hospital - Detroit

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2024-06-28
Est. Completion 2026-06
Phase Phase 2

Sponsor

Panafina

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06080789

The ClinicalTrials.gov registry entry for NCT06080789 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,315-participant average among 10 other Acute Pancreatitis trials with a reported enrollment target (98% lower). The listed sponsor is Panafina, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Pancreatitis appearing as the primary indexed condition, and to 1 intervention - of which RABI-767 is the first listed.

NCT06080789 reports 14 study locations spanning 13 distinct geographic areas - top geographies include Florida, Arkansas, California.

Frequently Asked Questions

What is clinical trial NCT06080789 about?

NCT06080789 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis". The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis. The main question the study aims to answer is: • Is a single-dose of R...

What is the current status of trial NCT06080789?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2024-06-28. Estimated completion is 2026-06.

What conditions does trial NCT06080789 study?

This clinical trial studies the following conditions: Acute Pancreatitis.

What interventions are being tested in trial NCT06080789?

The interventions under investigation include: RABI-767 (DRUG).

Who is sponsoring clinical trial NCT06080789?

This trial is sponsored by Panafina, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06080789 being conducted?

This trial has 14 study locations across Arkansas, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Pancreatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Pancreatitis

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.